A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa

The purpose of this study is to assess whether SD-101 (6%) is effective in treating the lesions in subjects with Simplex, Recessive Dystrophic, or Junctional Epidermolysis Bullosa (EB).

We are currently looking for subjects who meet the following criteria:

  • Have a documented diagnosis of Recessive Dystrophic EB, Junctional non-Herlitz EB, or EB Simplex
  • Are age 1 month or older and are willing to give consent, or if a minor, their parents or guardians are willing to give consent
  • Have a target wound of pre-specified size range and age at study entry

 

If you meet the inclusion criteria, you may be eligible to enroll in this study. Stanford University is one of several study sites involved in this study. You will be reimbursed for pre-approved costs for travel related to this trial.

You can learn more about Scioderm and this trial at www.sderm.com or at https://clinicaltrials.gov/ct2/show/NCT02384460.

If you would like more information, or have any questions regarding this study and/or the eligibility criteria, please contact our study coordinator, Melissa Barriga at (650) 850-1674 or mbarriga@stanford.edu.

For information about your rights as a research participant, please contact the Stanford Institutional Review Board (IRB) at 650-723-5244, or toll-free at 1-866-680-2906.